Mayo Clinic
200 1st Street SW
Rochester
Minnesota
55905
United States
Tel: 507-284-2511
Fax: 507-284-0161
Website: http://www.mayo.edu/
858 articles with Mayo Clinic
-
A cell and gene therapy accelerator formed by Mayo Clinic, Hibiscus BioVentures and Innoforce is officially up and running, the partners announced this week.
-
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic
8/29/2022
Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology.
-
Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests
8/9/2022
Metabolon , Inc. today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests.
-
A recent study found that over a span of ten years, the FDA approved cancer drugs approximately eight months earlier than the same drugs were greenlit by the European Commission (EC).
-
Elysium Health™ Announces Research at Mayo Clinic to Study Associations Between NAD+ Levels and Senescent Cell Burden and Develop Epigenetic Measures of Cellular Senescence
6/1/2022
Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.
-
Portland-based Children's Cancer Therapy Development Institute is discovering more targeted drugs for childhood cancers and driving them into clinical development with industry partner Artisan Biopharma.
-
Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
5/11/2022
Stella Diagnostics, Inc. announced that its abstract titled “Markers in STLA101 Assay Detects Differential Expression to Distinguish Between Intramucosal and Invasive Esophageal Adenocarcinoma” has been selected for presentation during Digestive Disease Week 2022, which will take place May 21–24, 2022 at the San Diego Convention Center in San Diego, CA.
-
There is always a fair amount of interest in anti-aging potential treatments, with an almost cyclical round of investment in the area. Here’s a look at some new research into aging.
-
Researchers are combining CAR-T cell therapy with cancer-killing viruses to create an even more potent treatment against solid cancer tumors.
-
Recipients Selected for the American Brain Foundation 2022 Cure One, Cure Many Award for the Early Diagnosis of Lewy Body Dementia
2/7/2022
The American Brain Foundation is thrilled to announce the recipients of the 2022 Cure One, Cure Many Award for the early diagnosis of Lewy body dementia: Owen A. Ross, PhD, Pamela J. McLean, PhD, and Bradley F. Boeve, MD from Mayo Clinic.
-
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
-
NaNotics to Collaborate with Mayo Clinic on Nanomedicine Cancer Treatment
1/4/2022
NaNotics LLC today announced a research collaboration with Mayo Clinic to develop a NaNot that targets the soluble form of PD-L1, a tumor-generated immune inhibitor.
-
Miromatrix Announces the First Successful Transplant of a Bioengineered Whole Organ in a Large Animal
10/7/2021
Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced it has successfully completed the first ever heterotopic implant of its bioengineered liver transplant into a large animal.
-
Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic
9/29/2021
Castle Creek Biosciences, Inc. today announced a research collaboration with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta
-
New Research from nference and Mayo Clinic Suggests Monoclonal Antibody Treatments Prevent Hospitalization for COVID-19 Patients
8/30/2021
nference, the AI-driven health technology company, announced publication of two studies providing important evidence that treatment of high-risk, mild to moderate COVID-19 patients with monoclonal antibodies significantly reduces risk of hospitalization.
-
Mayo Clinic and Debbie's Dream Foundation Hosts a Successful Gasgtroesophageal Cancer Educational Symposium
8/6/2021
Mayo Clinic and Debbie's Dream Foundation: Curing Stomach Cancer (DDF) co-hosted the Gastroesophageal Cancer Educational Symposium Clinic on Saturday, July 31, 2021 , in Rochester, Minnesota .
-
Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.
-
nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance
7/12/2021
nference today announced publication of a study in iScience that analyzed Mayo Clinic data with nference artificial intelligence (AI) software to suggest that anemia-related laboratory tests should be considered in risk stratification algorithms for COVID-19 patients.
-
Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform
7/6/2021
Tetherex Pharmaceuticals, Inc. today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
-
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.